TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Clinical safety rating: safe
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
| Metabolism | Triprolidine: Hepatic via CYP450 enzymes (major metabolites: hydroxylation products). Pseudoephedrine: Partially hepatic (N-demethylation) and renal excretion (55-75% unchanged in urine). |
| Excretion | Triprolidine: ~80% renal (mostly metabolites, <5% unchanged). Pseudoephedrine: ~70-90% renal (43-96% unchanged, depends on urine pH; acidic urine increases elimination, alkaline decreases). Biliary/fecal: negligible for both. |
| Half-life | Triprolidine: 3-5 hours (terminal). Pseudoephedrine: 5-8 hours (terminal, pH-dependent; urine pH 8: ~13 hours, pH 5: ~3 hours). Clinical: normal renal function. |
| Protein binding | Triprolidine: ~90% bound (serum proteins). Pseudoephedrine: ~20% bound (serum proteins). |
| Volume of Distribution | Triprolidine: ~2.5 L/kg (high tissue distribution). Pseudoephedrine: ~2.6-3.5 L/kg (extensive tissue distribution). |
| Bioavailability | Oral: Triprolidine: ~100% (well absorbed). Pseudoephedrine: ~90-100% (well absorbed). |
| Onset of Action | Oral: Triprolidine: 30-60 min. Pseudoephedrine: 30-60 min. |
| Duration of Action | Oral: Triprolidine: 4-6 hours (antihistamine). Pseudoephedrine: 4-6 hours (decongestant). Clinical: doses given q4-6h. |
| Molecular Weight | Triprolidine: 278.39 Da; Pseudoephedrine: 165.23 Da |
| Action Class | Antihistamine (H1-receptor antagonist) and decongestant (sympathomimetic amine) |
1 tablet (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4 to 6 hours; maximum 4 tablets per 24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer every 6 hours; GFR 10-29 mL/min: administer every 8 hours; GFR <10 mL/min: avoid use or administer every 12 hours with caution. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% or extend interval to every 8-12 hours; Child-Pugh Class C: avoid use. |
| Pediatric use | Children 6-12 years: half tablet (triprolidine 1.25 mg/pseudoephedrine 30 mg) orally every 4-6 hours, max 2 tablets per day; Children 2-5 years: consult physician (not typically recommended). |
| Geriatric use | Initiate at half the adult dose (e.g., half tablet) every 6 hours due to increased sensitivity and risk of anticholinergic effects; monitor for dizziness, sedation, and hypertension. |
| 1st trimester | Triprolidine-pseudoephedrine: Limited data; avoid first trimester due to potential vascular disruption and teratogenic risk. Pseudoephedrine may cause fetal tachycardia and is associated with gastroschisis in early pregnancy. |
| 2nd trimester | Use with caution; pseudoephedrine can cause uterine vasoconstriction and reduce placental perfusion. Triprolidine is generally considered low risk but lacks robust safety data. |
| 3rd trimester | Avoid near term; pseudoephedrine may cause fetal tachycardia, irritability, and has been associated with neonatal withdrawal. Triprolidine may cause neonatal respiratory depression if used near delivery. |
Clinical note
CNS depressants may enhance sedative effects May cause marked drowsiness and impair mental and physical abilities.
| FDA category | Animal |
| Placental transfer | Both triprolidine and pseudoephedrine cross the placenta. Pseudoephedrine is known to cross readily; triprolidine transfer is less documented but presumed. |
■ FDA Black Box Warning
None.
| Common Effects | Sedation |
| Serious Effects | CNS depression (sedation, drowsiness, dizziness), Cardiovascular effects (hypertension, tachycardia, arrhythmias, palpitations), Urinary retention, Increased intraocular pressure (angle-closure glaucoma), Seizures, Hallucinations (especially in children), Respiratory depression (in overdose) |
Severe hypertensionCoronary artery diseaseConcurrent use of MAOIs or within 14 daysAngle-closure glaucomaUrinary retention (e.g., from prostatic hypertrophy)Severe hepatic or renal impairment
| Precautions | Cardiovascular effects: Pseudoephedrine may cause hypertension, palpitations, tachycardia, and arrhythmias; use with caution in patients with cardiovascular disease., CNS depression: Triprolidine may cause sedation and impair mental alertness; avoid activities requiring full attention., Drug interactions: MAO inhibitors, sympathomimetics, anticholinergics, and CNS depressants may potentiate effects., Elderly and children: Increased sensitivity to anticholinergic effects; avoid in children <6 years unless directed by physician., Urinary retention: Triprolidine may exacerbate in patients with prostatic hypertrophy or bladder neck obstruction. |
Loading safety data…
| Breastfeeding | Triprolidine is excreted into breast milk in small amounts; pseudoephedrine is concentrated in breast milk and may irritate the infant or reduce milk production. Use with caution and monitor infant for irritability, insomnia, and tachycardia. Consider alternative antihistamines/decongestants. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Tripolidine hydrochloride: FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies. Pseudephedrine: FDA Pregnancy Category C. In first trimester, case-control studies suggest a slight increased risk of gastroschisis (OR ~1.8-2.0) with vasoconstrictors; avoid in first trimester. In second and third trimesters, risk is low, but high doses may reduce uterine blood flow. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate. In third trimester, assess fetal heart rate and uterine contractions if used near term. Watch for signs of uterine hyperstimulation with high doses. For prolonged use, monitor fetal growth via ultrasound. |
| Fertility Effects | No known adverse effects on fertility in humans. Pseudephedrine may theoretically impair spermatogenesis due to vasoconstriction, but clinical data are lacking. Tripolidine has no known effects. |
| Food/Dietary | Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as pseudoephedrine may have additive vasopressor effects. Caffeine-containing beverages may enhance stimulant effects and increase nervousness. Take with food or milk to reduce gastrointestinal upset. |
| Clinical Pearls | Triprolidine, a first-generation antihistamine, may cause significant sedation; caution when driving or operating machinery. Pseudoephedrine can elevate blood pressure and heart rate; avoid in uncontrolled hypertension or severe coronary artery disease. Use with caution in patients with benign prostatic hyperplasia due to risk of urinary retention. Consider alternative therapies in older adults due to anticholinergic burden. |
| Patient Advice | This medication may cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you. · Do not take with other products containing pseudoephedrine or other decongestants to avoid overdose. · Avoid alcohol as it can increase sedation and dizziness. · If you have high blood pressure, heart disease, or enlarged prostate, consult your doctor before use. · Do not exceed recommended dose; the maximum duration of use is 7 days. |